Loading stock data…
Altimmune (ALT)
$2.88+0.07 (+2.30%)
Market OpenUpdated 2:04 PM EDT
Altimmune, Inc., a late clinical stage biopharmaceutical company, focuses on developing novel therapies for serious liver diseases.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Altimmune, Inc. in the Healthcare sector is trading at $2.88 with a market capitalization of $509M. Wall Street consensus targets $15.45 (10 analysts), implying a +435.5% move over the next 12 months. The stock is currently near its 52-week low of $2.56, remaining 25.5% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality. The Whystock Score of 70/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +435.5% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0↓ | $26,000↑ | $5,000 | $5,000 | $5,000 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$24.24M↑ | -$28.89M↓ | -$20.86M↑ | -$22.92M↓ | -$21.82M |
| Net Income | -$22.56M↑ | -$27.36M↓ | -$19.01M↑ | -$22.15M↓ | -$19.57M |
Peer Comparison
JNJUNHPFE
Fundamentals
Altimmune, Inc., a late clinical stage biopharmaceutical company, focuses on developing novel therapies for serious liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 clinical trial ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$508.55M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-32.07%
Volume
Today's trading volume
1.77M
Recent News
Zacks Industry Outlook Indivior, Aurinia, Ironwood, Altimmune and Marker
Indivior, Aurinia, Ironwood, Altimmune and Marker have been highlighted in this Industry Outlook article.
5 Small Drug Stocks to Invest in Amid a Biotech Comeback
Innovation is at its peak in the Zacks Medical-Drugs industry. INDV, AUPH, IRWD, ALT and MRKR may prove to be good additions to one's portfolio.
Is Altimmune, Inc. (ALT) Still a Buy After Price Target Reduction to $20?
We recently compiled a list of the 10 Best Weight Loss Drug Stocks to Buy in 2026. Altimmune, Inc. (NASDAQ:ALT) is one of the best weight loss drugs on this list. TheFly reported on May 18 that H.C. Wainwright reiterated its Buy rating on ALT while reducing its price objective from $25 to $20. The adjustment was […]
Why Altimmune (ALT) Could Strengthen Its MASH Case With Pemvidutide’s Broader Metabolic Data
Altimmune, Inc. (NASDAQ:ALT) is one of the small-cap stocks with potential to rise 1000 percent. The company’s lead drug candidate, pemvidutide, is being developed for MASH, a serious liver disease tied to fat buildup, inflammation, and scarring in the liver. On May 28, Altimmune said new 48-week data from its IMPACT Phase 2b study showed […]
Why Is Altimmune (ALT) Down 11.3% Since Last Earnings Report?
Altimmune (ALT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.